ClinicalTrials.gg
CompletedNCT04702880Updated Jun 17, 2026Results posted

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

A Phase 2 interventional study of BMS-986012 and Carboplatin in Extensive-stage Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 39 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.

Enrollment
5th of 36
135 · median 48
Started
2021
with 4 others
Phase 2
22 of 36
4 open now
Registered
25th of 36
by date

Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 5th largest by enrollment, is one of 5 that started in 2021, is one of 22 in phase 2, and was the 25th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing carboplatin in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

03

Conditions studied

  • Extensive-stage Small Cell Lung Cancer

Keywords

  • BMS-986012
  • Carboplatin
  • Etoposide
  • Extensive-stage small cell lung cancer
  • Fucosyl
  • Nivolumab
  • Targeted SCLC therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically documented extensive-stage small cell lung cancer (ES-SCLC) and extensive-stage disease (American Joint Committee on Cancer, 8th edition, Stage IV [T any, N any, M1a, M1b, or M1c], or T3-4 due to multiple lung nodules that are too extensive or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan)
  • Participants taking part in the separate PET tracer sub-study must provide a fresh tumor from any disease site (primary or )
  • Archived tumor specimens, in the form of blocks or sectioned slides, are mandatory for all participants except those participating in the separate PET tracer sub-study for whom the archived tumor specimen is optional
  • performance status (ECOG PS) 0 or 1
  • At least 1 by computed tomography (CT) or magnetic resonance imaging (MRI) per version 1.1 (RECIST v1.1) criteria
  • Adequate hematologic and end organ function
  • Must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding. Japan only: participation in the study is not allowed even if breastfeeding is suspended
  • Prior chemotherapy, radiation therapy, or biologic therapy for SCLC. Previously treated limited stage SCLC (LS-SCLC) participants are also excluded
  • Symptomatic brain or other central nervous system (CNS)
  • Paraneoplastic syndrome requiring systemic treatment
  • History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan
  • Grade ≥ 2 peripheral sensory neuropathy at study entry
  • Significant uncontrolled cardiovascular disease
  • Active, known or suspected autoimmune disease or inflammatory disorder

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Arm A: Carboplatin + Etoposide + Nivolumab + BMS-986012

    Biological: BMS-986012 · Drug: Carboplatin · Drug: Etoposide · Biological: Nivolumab

  • Experimental
    Arm B: Carboplatin + Etoposide + Nivolumab

    Drug: Carboplatin · Drug: Etoposide · Biological: Nivolumab

Interventions

  • BiologicalBMS-986012

    Specified dose on specified days

    Also known as: Fucosyl-GM1 Antibody

  • Specified dose on specified days

  • Specified dose on specified days

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

  2. Number of Participants With Serious Adverse Events

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

  3. Number of Participants With Adverse Events Leading to Discontinuation

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)

  4. Number of Participants Who Died

    Number of participants who died due to any cause.

    Time frame: From first dose to primary cutoff date (Up to approximately 43 months)

  5. Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

    PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

    Time frame: From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)

Secondary outcomes

  1. Progression Free Survival Rate (PFSR) at 6 and 12 Months

    PFSR is defined as the percentage of participants progression free at 6 and 12 months. PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Blinded Independent Central Review (BICR) and by investigator, or death from any cause. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

    Time frame: 6 and 12 months

  2. Progression Free Survival (PFS) Per Investigator

    PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Investigator or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

    Time frame: From randomization to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 56 months)

  3. Objective Response Rate (ORR)

    ORR per Blinded Independent Central Review (BICR) and per investigator is defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

    Time frame: From randomization to the date of first documented response (Up to approximately 56 months)

  4. Duration of Response (DoR)

    DoR per Blinded Independent Central Review and per investigator is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

    Time frame: From randomization to the date of the documentation of disease progression or death due to any cause, whichever is earlier (Up to approximately 56 months)

  5. Time to Response (TTR)

    TTR per Blinded Independent Central Review (BICR) and per investigator is defined for participants who had a confirmed CR or PR as the time from the date of randomization to date of first documented CR or PR per RECIST v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

    Time frame: From randomization to the date of first documented CR or PR (Up to approximately 56 months)

  6. Overall Survival (OS)

    OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.

    Time frame: From randomization to the date of death due to any cause (Up to approximately 56 months)

  7. Overall Survival Rate (OSR) at 12 and 24 Months

    OSR is defined as the percentage of participants surviving at 12 and 24 months. OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.

    Time frame: 12 and 24 months

  8. Number of Participants With Anti-Nivolumab Antibody (ADA)

    ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. Baseline ADA Positive: A participant with baseline ADA-positive sample.

    Time frame: From baseline up to approximately 56 months

07

Results

Posted Jun 17, 2026

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneArm AArm B
Started6768
Completed6665
Not completed13
Withdrew: Participant request to discontinue study treatment01
Withdrew: Withdrawal by subject01
Withdrew: Participant no longer meets study criteria10
Withdrew: Other reasons01
Treatment - Induction Phase
Participant flow — Treatment - Induction Phase
MilestoneArm AArm B
Started6665
Completed5653
Not completed1012
Withdrew: Participant request to discontinue study10
Withdrew: Withdrawal by subject01
Withdrew: Death10
Withdrew: Disease progression23
Withdrew: Study drug toxicity36
Withdrew: Adverse event unrelated to study drug32
Treatment - Maintenance Phase
Participant flow — Treatment - Maintenance Phase
MilestoneArm AArm B
Started5652
Did not enter maintenance phase01
Completed62
Not completed5050
Withdrew: Withdrawal by subject01
Withdrew: Death10
Withdrew: Disease progression4242
Withdrew: Study drug toxicity14
Withdrew: Adverse event unrelated to study drug20
Withdrew: Other reasons11
Withdrew: Participant request to discontinue study21
Withdrew: Transitioned to rollover study11

Outcome measures

SecondaryProgression Free Survival Rate (PFSR) at 6 and 12 Months

PFSR is defined as the percentage of participants progression free at 6 and 12 months. PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Blinded Independent Central Review (BICR) and by investigator, or death from any cause. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

Time frame:
6 and 12 months
Reported as:
Number · Percentage of participants
Progression Free Survival Rate (PFSR) at 6 and 12 Months
Percentage of participantsArm AArm B
6 months - BICR48.7 (35.6 to 60.6)43.1 (30.0 to 55.5)
6 months - Investigator56.4 (43.1 to 67.7)42.8 (30.1 to 55.0)
12 months - BICR21.0 (11.4 to 32.5)22.2 (12.2 to 34.0)
12 months Investigator18.1 (9.6 to 28.7)19.6 (10.6 to 30.8)
SecondaryProgression Free Survival (PFS) Per Investigator

PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by Investigator or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

Time frame:
From randomization to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 56 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Investigator
MonthsArm AArm B
Progression Free Survival (PFS) Per Investigator6.47 (5.13 to 7.89)5.09 (4.76 to 6.67)
Statistical analysis
  • Arm A vs Arm B · Hazard ratio (hr): 0.87 · 95% CI 0.59 to 1.29Stratified Cox proportional hazard model
SecondaryObjective Response Rate (ORR)

ORR per Blinded Independent Central Review (BICR) and per investigator is defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

Time frame:
From randomization to the date of first documented response (Up to approximately 56 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsArm AArm B
Per BICR73.1 (60.9 to 83.2)66.2 (53.7 to 77.2)
Per Investigator74.6 (62.5 to 84.5)61.8 (49.2 to 73.3)
SecondaryDuration of Response (DoR)

DoR per Blinded Independent Central Review and per investigator is defined for participants who have a confirmed CR or PR as the date from first documented CR or PR per RECIST v1.1 to the date of the documentation of disease progression or death due to any cause, whichever is earlier. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

Time frame:
From randomization to the date of the documentation of disease progression or death due to any cause, whichever is earlier (Up to approximately 56 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsArm AArm B
per BICR6.41 (4.30 to 7.39)4.50 (3.48 to 5.49)
per Investigator5.29 (4.73 to 6.87)4.96 (3.48 to 6.70)
SecondaryTime to Response (TTR)

TTR per Blinded Independent Central Review (BICR) and per investigator is defined for participants who had a confirmed CR or PR as the time from the date of randomization to date of first documented CR or PR per RECIST v1.1. CR=Disappearance of all target lesions. PR=At least 30% decrease in the sum of diameters of target lesions.

Time frame:
From randomization to the date of first documented CR or PR (Up to approximately 56 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsArm AArm B
per BICR1.51 (1.3 to 3.0)1.58 (1.2 to 5.2)
per Investigator1.51 (1.2 to 5.0)1.63 (1.2 to 18.1)
PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm AArm B
Number of Participants With Adverse Events6665
PrimaryNumber of Participants With Serious Adverse Events

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsArm AArm B
Number of Participants With Serious Adverse Events3834
PrimaryNumber of Participants With Adverse Events Leading to Discontinuation

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsArm AArm B
Number of Participants With Adverse Events Leading to Discontinuation1316
PrimaryNumber of Participants Who Died

Number of participants who died due to any cause.

Time frame:
From first dose to primary cutoff date (Up to approximately 43 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsArm AArm B
Number of Participants Who Died4753
PrimaryProgression Free Survival (PFS) Per Blinded Independent Central Review (BICR)

PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

Time frame:
From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
MonthsArm AArm B
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)5.78 (4.99 to 7.89)5.59 (4.86 to 6.57)
Statistical analysis
  • Arm A vs Arm B · Log Rank · p = 0.3676 · Hazard ratio (hr): 0.83 · 95% CI 0.55 to 1.25Stratified Cox proportional hazard model
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.

Time frame:
From randomization to the date of death due to any cause (Up to approximately 56 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm AArm B
Overall Survival (OS)16.26 (12.22 to 23.66)13.08 (9.72 to 16.62)
Statistical analysis
  • Arm A vs Arm B · Hazard ratio (hr): 0.80 · 95% CI 0.54 to 1.18Stratified Cox proportional hazard model
SecondaryOverall Survival Rate (OSR) at 12 and 24 Months

OSR is defined as the percentage of participants surviving at 12 and 24 months. OS is defined as the time from randomization to the time of death due to any cause. OS will be estimated using the Kaplan-Meier method.

Time frame:
12 and 24 months
Reported as:
Number · Percentage of participants
Overall Survival Rate (OSR) at 12 and 24 Months
Percentage of participantsArm AArm B
12 months64.7 (51.9 to 75.0)51.7 (38.8 to 63.0)
24 months37.8 (26.1 to 49.5)25.0 (15.2 to 36.1)
SecondaryNumber of Participants With Anti-Nivolumab Antibody (ADA)

ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. Baseline ADA Positive: A participant with baseline ADA-positive sample.

Time frame:
From baseline up to approximately 56 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-Nivolumab Antibody (ADA)
ParticipantsArm A
BMS-986012 ADA Positive2
Nivolumab ADA Positive4
Post-hocNumber of Participants With Adverse Events - Extended Collection

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days post last dose (Up to approximately 47 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events - Extended Collection
ParticipantsArm AArm B
Number of Participants With Adverse Events - Extended Collection6665
Post-hocNumber of Participants With Serious Adverse Events - Extended Collection

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose to 100 days post last dose (Up to approximately 47 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events - Extended Collection
ParticipantsArm AArm B
Number of Participants With Serious Adverse Events - Extended Collection3834
Post-hocNumber of Participants With Adverse Events Leading to Discontinuation - Extended Collection

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose to 100 days post last dose (Up to approximately 47 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection
ParticipantsArm AArm B
Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection1315
Post-hocNumber of Participants Who Died - Extended Collection

Number of participants who died due to any cause.

Time frame:
From first dose to 100 days post last dose (Up to approximately 47 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died - Extended Collection
ParticipantsArm AArm B
Number of Participants Who Died - Extended Collection5056
Post-hocProgression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection

PFS based on RECIST v1.1 is defined as the time from randomization to the date of the first documented tumor progression by BICR or death from any cause. Estimates are based on Kaplan-Meier product-limit method. Progressive disease=At least a 20% increase in the sum of diameters of target lesions.

Time frame:
From randomization to the date of the first documented tumor progression, or death, whichever occurs first (Up to approximately 56 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection
MonthsArm AArm B
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR) - Extended Collection5.78 (4.99 to 7.89)5.59 (4.86 to 6.57)
Statistical analysis
  • Arm A vs Arm B · Log Rank · p = 0.3717 · Hazard ratio (hr): 0.83 · 95% CI 0.56 to 1.25Stratified Cox proportional hazard model

Adverse events

Collected over All-Cause Mortality (ACM) was assessed from randomization until their study completion (Up to approximately 56 months). Adverse Events (AEs) and Serious Adverse (SAEs) were assessed from first dose to 100 days post last dose (Up to approximately 47 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A50/67 (74.6%)38/66 (57.6%)62/66 (93.9%)
Arm B56/68 (82.4%)34/65 (52.3%)62/65 (95.4%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventArm AArm B
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/663/65
Febrile neutropeniaBlood and lymphatic system disorders3/665/65
PneumoniaInfections and infestations4/664/65
Septic shockInfections and infestations0/663/65
ThrombocytopeniaBlood and lymphatic system disorders0/662/65
SepsisInfections and infestations2/662/65
Respiratory failureRespiratory, thoracic and mediastinal disorders0/662/65
Cardio-respiratory arrestCardiac disorders2/661/65
COVID-19Infections and infestations2/660/65
Clostridium difficile colitisInfections and infestations2/660/65
Most frequent other events
Showing 10 of 50
Most frequent other events
EventArm AArm B
PruritusSkin and subcutaneous tissue disorders41/6612/65
AnaemiaBlood and lymphatic system disorders26/6639/65
NauseaGastrointestinal disorders19/6623/65
NeutropeniaBlood and lymphatic system disorders22/6621/65
ThrombocytopeniaBlood and lymphatic system disorders22/6621/65
AlopeciaSkin and subcutaneous tissue disorders20/6618/65
DiarrhoeaGastrointestinal disorders18/6612/65
FatigueGeneral disorders and administration site conditions17/6610/65
Decreased appetiteMetabolism and nutrition disorders13/6616/65
ConstipationGastrointestinal disorders15/6615/65

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm AArm BTotal
Mean66.0 ± 7.2966.0 ± 8.3766.0 ± 7.82
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female243559
Male433376
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino112
Not Hispanic or Latino414788
Unknown or Not Reported252045
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian4610
Native Hawaiian or Other Pacific Islander000
Black or African American101
White6062122
More than one race000
Unknown or Not Reported202
08

Study locations

39 sites
  • Local Institution - 0075
    Birmingham, Alabama 35249, United States
  • Local Institution - 0022
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0002
    Durham, North Carolina 27710, United States
  • Local Institution - 0060
    Cincinnati, Ohio 45267, United States
  • Local Institution
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0067
    Cleveland, Ohio 44106-1716, United States
  • Local Institution - 0081
    Nashville, Tennessee 37203, United States
  • Local Institution
    Dallas, Texas 75390, United States
  • Local Institution - 0003
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0023
    Greenslopes, Queensland 4120, Australia
  • Local Institution - 0001
    Malvern, Victoria 3144, Australia
  • Local Institution - 0004
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0051
    Charleroi, Hainaut 6060, Belgium
  • Local Institution - 0034
    Ghent, 9000, Belgium
  • Local Institution - 0050
    Liège, 4000, Belgium
  • Local Institution - 0012
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0064
    Brampton, Ontario L6R 3J7, Canada
  • Local Institution - 0045
    Heraklion, Irakleío 715 00, Greece
  • Local Institution - 0036
    Athens, 11527, Greece
  • Local Institution - 0038
    Athens, 185 47, Greece
  • Local Institution - 0030
    Peschiera del Garda, 37019, Italy
  • Local Institution - 0031
    Pisa, 56124, Italy
  • Local Institution - 0029
    Rozzano, 20089, Italy
  • Local Institution - 0073
    Sendai, Miyagi 980-0873, Japan
  • Local Institution - 0070
    Ōsaka-sayama, Osaka 589-8511, Japan
  • Local Institution - 0069
    Takatsuki, Osaka 5698686, Japan
  • Local Institution - 0077
    Ina-machi, Saitama 362-0806, Japan
  • Local Institution - 0039
    Amsterdam, North Holland 1081 HV, Netherlands
  • Local Institution - 0066
    Arnhem, 6815 AD, Netherlands
  • Local Institution - 0040
    Groningen, 9700RB, Netherlands
  • Local Institution - 0049
    Gdansk, 80-214, Poland
  • Local Institution - 0048
    Lodz, 93-338, Poland
  • Local Institution - 0043
    Bucharest, 022328, Romania
  • Local Institution - 0042
    Cluj-Napoca, 400015, Romania
  • Local Institution - 0041
    Craiova, 200542, Romania
  • Local Institution - 0007
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Local Institution - 0021
    Madrid, 28041, Spain
  • Local Institution - 0005
    Majadahonda, 28222, Spain
  • Local Institution - 0006
    Málaga, 29010, Spain
09

References and documents

Publications

  • Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N. BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study. JTO Clin Res Rep. 2022 Aug 27;3(11):100400. doi: 10.1016/j.jtocrr.2022.100400. eCollection 2022 Nov. PubMed 36275912 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in May 2025, 50 months.

Results were first posted in Jun 2026, 1 year after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 50 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Mar 17, 2021
Primary completionActual
May 22, 2025
CompletionActual
Nov 28, 2025
Results first posted
Jun 17, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04702880
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Mar 17, 2021
Primary completion
May 22, 2025
Completion
Nov 28, 2025
Results posted
Jun 17, 2026
Last update
Jun 17, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Etoposide

Start the discussion